HomeCompareANPDY vs ABBV

ANPDY vs ABBV: Dividend Comparison 2026

ANPDY yields 3.29% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ANPDY wins by $659.23M in total portfolio value· pulled ahead in Year 2
10 years
ANPDY
ANPDY
● Live price
3.29%
Share price
$247.16
Annual div
$8.14
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$659.33M
Annual income
$622,980,530.29
Full ANPDY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ANPDY vs ABBV

📍 ANPDY pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodANPDYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ANPDY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ANPDY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ANPDY
Annual income on $10K today (after 15% tax)
$279.87/yr
After 10yr DRIP, annual income (after tax)
$529,533,450.75/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ANPDY beats the other by $529,512,394.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ANPDY + ABBV for your $10,000?

ANPDY: 50%ABBV: 50%
100% ABBV50/50100% ANPDY
Portfolio after 10yr
$329.72M
Annual income
$311,502,651.03/yr
Blended yield
94.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ANPDY
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
5.2
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ANPDY buys
0
ABBV buys
0
No recent congressional trades found for ANPDY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricANPDYABBV
Forward yield3.29%3.06%
Annual dividend / share$8.14$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$659.33M$102.3K
Annual income after 10y$622,980,530.29$24,771.77
Total dividends collected$656.67M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: ANPDY vs ABBV ($10,000, DRIP)

YearANPDY PortfolioANPDY Income/yrABBV PortfolioABBV Income/yrGap
1$11,359$658.51$11,550$430.00$191.00ABBV
2← crossover$13,552$1,398.07$13,472$627.96+$80.00ANPDY
3$17,618$3,117.78$15,906$926.08+$1.7KANPDY
4$26,428$7,576.30$19,071$1,382.55+$7.4KANPDY
5$49,520$21,242.40$23,302$2,095.81+$26.2KANPDY
6$127,386$74,399.82$29,150$3,237.93+$98.2KANPDY
7$494,037$357,733.88$37,536$5,121.41+$456.5KANPDY
8$3,121,865$2,593,244.80$50,079$8,338.38+$3.07MANPDY
9$33,970,199$30,629,803.90$69,753$14,065.80+$33.90MANPDY
10$659,328,643$622,980,530.29$102,337$24,771.77+$659.23MANPDY

ANPDY vs ABBV: Complete Analysis 2026

ANPDYStock

ANTA Sports Products Limited, together with its subsidiaries, designs, develops, manufactures, and markets sporting footwear, apparel, and accessories worldwide. The company offers sportswear, including running, cross-training, basketball, soccer, boxing, winter sports, boxing, taekwondo, gymnastics, weightlifting, wrestling, outdoor sports, women's fitness, and skiing products, as well as sports fashion clothing, kid's sports fashion clothing and sportswear, and leisure footwear products under the FILA, FILA KIDS, FILA FUSION, KINGKOW, KOLON SPORT, SPRANDI, FILA FUSION, ANTA, DESCENTE, and ANTA KIDS brands. It also provides management, product design, logistics, and information technology services; manufactures shoe soles; holds trademarks; and develops and manages properties. As of December 31, 2021, it operated 9,403 ANTA stores; 2,054 FILA stores; 182 DESCENTE stores; and 152 KOLON SPORT stores. It also exports and imports sporting shoes. The company was founded in 1991 and is headquartered in Jinjiang, the People's Republic of China. ANTA Sports Products Limited is a subsidiary of Anta International Group Holdings Limited.

Full ANPDY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ANPDY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ANPDY vs SCHDANPDY vs JEPIANPDY vs OANPDY vs KOANPDY vs MAINANPDY vs JNJANPDY vs MRKANPDY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.